Cancer vaccination drives nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype

Kyung Hee Noh, Young Ho Lee, Ju Hong Jeon, Tae Heung Kang, Chih Ping Mao, T. C. Wu, Tae Woo Kim

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Due to the exquisite specificity and potency of the immune system, vaccination is in theory the most precise and powerful approach for controlling cancer. However, current data from clinical trials indicate that vaccination rarely yields significant benefits for cancer patients in terms of tumor progression and long-term survival. The poor clinical outcomes of vaccination are primarily caused by mechanisms of immune tolerance, especially within the tumor microenvironment. Here, we report that vaccination drives the evolution of tumor cells toward an immune-resistant and stem-like phenotype that promotes tumor growth and nullifies the CTL response. The emergence of this phenotype required the transcription factor Nanog, which is induced as a consequence of immune selection. Nanog expression enhanced the stem-like features of tumor cells and protected them from killing by tumor-reactive CTLs. Delivery of siNanog into tumor-bearing mice rendered the tumor vulnerable to immune surveillance and strongly suppressed its growth. Together, our findings show tumor adaptation to vaccination through gain of an immune-resistant, stem-like phenotype and identify Nanog as a central molecular target in this process. Future vaccination technology should consider Nanog an important target to enhance the immunotherapeutic response.

Original languageEnglish
Pages (from-to)1717-1727
Number of pages11
JournalCancer Research
Volume72
Issue number7
DOIs
Publication statusPublished - 2012 Apr 1

Fingerprint

Vaccination
Phenotype
Neoplasms
Immune Tolerance
Tumor Microenvironment
Growth
Immune System
Transcription Factors
Clinical Trials
Technology
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Cancer vaccination drives nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. / Noh, Kyung Hee; Lee, Young Ho; Jeon, Ju Hong; Kang, Tae Heung; Mao, Chih Ping; Wu, T. C.; Kim, Tae Woo.

In: Cancer Research, Vol. 72, No. 7, 01.04.2012, p. 1717-1727.

Research output: Contribution to journalArticle

Noh, Kyung Hee ; Lee, Young Ho ; Jeon, Ju Hong ; Kang, Tae Heung ; Mao, Chih Ping ; Wu, T. C. ; Kim, Tae Woo. / Cancer vaccination drives nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype. In: Cancer Research. 2012 ; Vol. 72, No. 7. pp. 1717-1727.
@article{748dbb8518ae483f962cc834cffaa4d2,
title = "Cancer vaccination drives nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype",
abstract = "Due to the exquisite specificity and potency of the immune system, vaccination is in theory the most precise and powerful approach for controlling cancer. However, current data from clinical trials indicate that vaccination rarely yields significant benefits for cancer patients in terms of tumor progression and long-term survival. The poor clinical outcomes of vaccination are primarily caused by mechanisms of immune tolerance, especially within the tumor microenvironment. Here, we report that vaccination drives the evolution of tumor cells toward an immune-resistant and stem-like phenotype that promotes tumor growth and nullifies the CTL response. The emergence of this phenotype required the transcription factor Nanog, which is induced as a consequence of immune selection. Nanog expression enhanced the stem-like features of tumor cells and protected them from killing by tumor-reactive CTLs. Delivery of siNanog into tumor-bearing mice rendered the tumor vulnerable to immune surveillance and strongly suppressed its growth. Together, our findings show tumor adaptation to vaccination through gain of an immune-resistant, stem-like phenotype and identify Nanog as a central molecular target in this process. Future vaccination technology should consider Nanog an important target to enhance the immunotherapeutic response.",
author = "Noh, {Kyung Hee} and Lee, {Young Ho} and Jeon, {Ju Hong} and Kang, {Tae Heung} and Mao, {Chih Ping} and Wu, {T. C.} and Kim, {Tae Woo}",
year = "2012",
month = "4",
day = "1",
doi = "10.1158/0008-5472.CAN-11-3758",
language = "English",
volume = "72",
pages = "1717--1727",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "7",

}

TY - JOUR

T1 - Cancer vaccination drives nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype

AU - Noh, Kyung Hee

AU - Lee, Young Ho

AU - Jeon, Ju Hong

AU - Kang, Tae Heung

AU - Mao, Chih Ping

AU - Wu, T. C.

AU - Kim, Tae Woo

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Due to the exquisite specificity and potency of the immune system, vaccination is in theory the most precise and powerful approach for controlling cancer. However, current data from clinical trials indicate that vaccination rarely yields significant benefits for cancer patients in terms of tumor progression and long-term survival. The poor clinical outcomes of vaccination are primarily caused by mechanisms of immune tolerance, especially within the tumor microenvironment. Here, we report that vaccination drives the evolution of tumor cells toward an immune-resistant and stem-like phenotype that promotes tumor growth and nullifies the CTL response. The emergence of this phenotype required the transcription factor Nanog, which is induced as a consequence of immune selection. Nanog expression enhanced the stem-like features of tumor cells and protected them from killing by tumor-reactive CTLs. Delivery of siNanog into tumor-bearing mice rendered the tumor vulnerable to immune surveillance and strongly suppressed its growth. Together, our findings show tumor adaptation to vaccination through gain of an immune-resistant, stem-like phenotype and identify Nanog as a central molecular target in this process. Future vaccination technology should consider Nanog an important target to enhance the immunotherapeutic response.

AB - Due to the exquisite specificity and potency of the immune system, vaccination is in theory the most precise and powerful approach for controlling cancer. However, current data from clinical trials indicate that vaccination rarely yields significant benefits for cancer patients in terms of tumor progression and long-term survival. The poor clinical outcomes of vaccination are primarily caused by mechanisms of immune tolerance, especially within the tumor microenvironment. Here, we report that vaccination drives the evolution of tumor cells toward an immune-resistant and stem-like phenotype that promotes tumor growth and nullifies the CTL response. The emergence of this phenotype required the transcription factor Nanog, which is induced as a consequence of immune selection. Nanog expression enhanced the stem-like features of tumor cells and protected them from killing by tumor-reactive CTLs. Delivery of siNanog into tumor-bearing mice rendered the tumor vulnerable to immune surveillance and strongly suppressed its growth. Together, our findings show tumor adaptation to vaccination through gain of an immune-resistant, stem-like phenotype and identify Nanog as a central molecular target in this process. Future vaccination technology should consider Nanog an important target to enhance the immunotherapeutic response.

UR - http://www.scopus.com/inward/record.url?scp=84859417830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859417830&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-11-3758

DO - 10.1158/0008-5472.CAN-11-3758

M3 - Article

C2 - 22337995

AN - SCOPUS:84859417830

VL - 72

SP - 1717

EP - 1727

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 7

ER -